SBIR-STTR Award

Releasable Site-Specific Attachment of Macromolecules to Therapeutic Peptides
Award last edited on: 7/21/10

Sponsored Program
SBIR
Awarding Agency
NIH : NIDDK
Total Award Amount
$143,958
Award Phase
1
Solicitation Topic Code
-----

Principal Investigator
Gary W Ashley

Company Information

Prolynx LLC

455 Mission Bay Boulevard South Suite 145
San Francisco, CA 94158
   (415) 552-5306
   bd@prolynxllc.com
   www.prolynxllc.com
Location: Single
Congr. District: 12
County: San Francisco

Phase I

Contract Number: 1R43DK088481-01
Start Date: 5/21/10    Completed: 10/31/10
Phase I year
2010
Phase I Amount
$143,958
Many potent and specific peptides suffer problems of short or sub-optimal duration. A possible solution to such problems involves conjugation to macromolecules such as polyethylene glycol (PEG) that are slowly eliminated from the body, and thus prolongs the action of the attached peptide. For peptide therapeutics, it is usually essential that the unchanged drug be released from the macromolecule with timing appropriate to satisfy the need. Current approaches often use cleavable linkers to attach the peptide to the macromolecule by a linker that cleaves because of the effect of an enzyme, or physiological environment. Although such approaches are often successful, they usually do not allow prediction or control of the rate of drug release and hence the duration of action. The objective of this project is a) to develop a novel platform technology that allows site-specific attachment of a macromolecule to peptides, and b) to develop technology for predictable, chemically-controlled release of such peptides. If successful, a) we will have developed general technology for controlled release of peptides from macromolecules that could be broadly applied, and set the stage for future applications of such technology to therapeutic peptides.

Public Health Relevance:
We propose to develop a novel platform technology that allows site-specific attachment of macromolecules to peptides, and predictable, controlled release of the native peptides that will allow an increase in the duration of their action. If successful, we will have developed general technology for controlled release of therapeutic peptides from macromolecules that could be broadly applied to the area of therapeutic peptides.

Thesaurus Terms:
Amines; Area; Binding; Binding (Molecular Function); Chemistry; Cleaved Cell; Diabetes Mellitus; Drugs; Environment; Enzymes; Evaluation; Ex4 Peptide; Exendin 4; Future; Government; Hand; Humulin R; Iapp; Insulin; Insulin (Ox), 8a-L-Threonine-10a-L-Isoleucine-30b-L-Threonine-; Insulin, Regular; Insulinoma Amyloid Peptide; Left; Link; Macrogols; Medication; Mercaptans; Mercapto Compounds; Modeling; Molecular Interaction; Novolin R; Peg; Peptide Synthesis; Peptides; Persons; Pharmaceutic Preparations; Pharmaceutical Preparations; Phase; Physiologic; Physiological; Polyethylene Glycols; Polyethylene Oxide; Polyethyleneoxide; Polyoxyethylenes; Preparation; Proteins; Reaction; Reagent; Science Of Chemistry; Series; Side; Site; Solid; Solutions; Staging; Sulfhydryl Compounds; Synthesis Chemistry; Synthetic Chemistry; Txt; Technology; Text; Therapeutic; Thiols; Time; Amino Group; Amlintide; Amylin; Base; Cleaved; Controlled Release; Design; Designing; Diabetes; Diabetes Associated Peptide; Drug/Agent; Exenatide; Gene Product; In Vivo; Insulinoma Amyloid Polypeptide; Islet Amyloid Polypeptide; Macromolecule; Novel; Pancreatic Amylin; Public Health Relevance; Sulfhydryl Group

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----